Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding a Reduction in the Amounts of Capital and Capital Reserve and the Disposal of Surplus

The Company will reduce its stated capital by ¥5,772,971 thousand and its capital reserve by ¥5,784,268 thousand, transferring the amounts to other capital surplus. It will then transfer ¥11,557,239 thousand from other capital surplus to retained earnings brought forward to offset the accumulated deficit. The number of shares and net assets will remain unchanged.

Worth reading
27Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
11557239
¥ thousand
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

発行済株式総数

No change

Procedures under the Corporate Code of Conduct
The proposal will be submitted to the 16th Annual General Meeting of Shareholders, scheduled for 26 June 2026.
Impact on Business Performance
No impact on business results
Details of issuance or disposal
ItemDetails
Total number of issued sharesNo change
Procedures under the Corporate Code of ConductThe proposal will be submitted to the 16th Annual General Meeting of Shareholders, scheduled for 26 June 2026.
Impact on Business PerformanceNo impact on business results
Items this document does not state (25)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To offset the deficit in retained earnings brought forward as part of efforts to strengthen the Company's financial position.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Reduction in the Amounts of Capital and Capital Reserve and the Disposal of Surplus | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori